GSK Lamictal Bipolar Claim "Approvable"; Exact Indication Under Discussion
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline is discussing the scope of a bipolar indication for Lamictal following an April 4 "approvable" letter for the new claim.